Allergy/Asthma

Atopic dermatitis in children and adults can improve with the treatment of a solution containing Roseomonas mucosa, which decreases the severity of the disease and reduces the rate of Staphylococcus aureus colonization in children, according to findings from a phase 1 and 2 trial.

Food allergies were the most common of allergic conditions found in children with autism, according to findings recently published in JAMA Network Open.

Respiratory viruses, including influenza, were associated with an increased risk of treatment failure in children who presented to the ED with moderate or severe asthma exacerbations, according to recently published study results in Pediatrics.

Dupilumab, a drug typically used to treat moderate-to-severe eczema, may assist in reducing the rate of severe exacerbation in those aged 12 years and older with uncontrolled asthma.

Sanofi and Regeneron’s drug Dupixent led to clearer skin in most patients in phase 3 trial involving 12- to 17-year-olds with moderate-to-severe atopic dermatitis, according to a press release from the company.

The skin of children with early-onset atopic dermatitis exhibits significantly different phenotypes when compared with the skin of adults with a long-standing history with the disease, according to research published in The Journal of Allergy and Clinical Immunology.

GlaxoSmithKline announced that the FDA has approved Arnuity Ellipta, a once-daily inhaled corticosteroid, for treating asthma in children aged as young as 5 years, according to a company press release.

All children in one cohort who were labeled as penicillin allergic but tested negative for the allergy were able to tolerate a challenge, according to findings published in Pediatrics.

Pediatricians and allergists are facing a growing number of children with food allergy and are weighing the benefits and the risks of new and time-tested forms of immunotherapy treatment for these patients.